Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VTRS - Viatris Inc


IEX Last Trade
12.455
0.005   0.040%

Share volume: 102,849
Last Updated: Fri 27 Dec 2024 08:30:27 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%

$12.45
0.01
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
23%
Profitability 6%
Dept financing 43%
Liquidity 55%
Performance 27%
Company vs Stock growth
vs
Performance
5 Days
0.56%
1 Month
-4.99%
3 Months
8.74%
6 Months
19.85%
1 Year
16.62%
2 Year
13.77%
Key data
Stock price
$12.46
P/E Ratio 
-22.30
DAY RANGE
$12.40 - $12.66
EPS 
-$0.54
52 WEEK RANGE
$10.18 - $13.62
52 WEEK CHANGE
$15.97
MARKET CAP 
14.418 B
YIELD 
3.89%
SHARES OUTSTANDING 
1.194 B
DIVIDEND
$0.12
EX-DIVIDEND DATE
08/23/2024
NEXT EARNINGS DATE
11/05/2024
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$14,016,529
AVERAGE 30 VOLUME 
$9,375,591
Company detail
CEO: Michael Goettler
Region: US
Website: viatris.com
Employees: 37,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Viatris Inc. operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.

Recent news